EUVIMEDEUVIMED entdecken
Crossref

Re‐vaccination against SARS ‐ CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates

Marios Tsoutsoukis iD, Chloe Anthias, Sandra Easdale, Emma Nicholson iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Marios Tsoutsoukis und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden NHS Hospital, Sutton, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, COVID-19, Seroconversion, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with haematological malignancies often exhibit reduced antibody responses to severe acute respiratory syndrome‐related coronavirus vaccines, especially those who have undergone allogeneic haematopoietic stem cell transplantation (HSCT). Limited data exist on vaccine efficacy in this group. In a retrospective analysis of 75 post‐HSCT patients, we assessed serologic responses to one to four doses of Pfizer‐BioNTech (PB), AstraZeneca (AZ) or Moderna (MU) vaccines within 2 years post‐transplant. Seroconversion rates were 50.7%, 78%, 79% and 83% after the first to fourth doses respectively. The median time from allograft to first re‐vaccination was 145 days (range 79–700). Failure to respond to the first vaccine dose was linked to acute GVHD ( p = 0.042) and rituximab treatment within 12 months ( p = 0.019). A trend was observed with chronic GVHD and seroconversion failure after the second ( p = 0.07) and third ( p = 0.09) doses. Patients vaccinated before HSCT showed better antibody responses post‐transplant ( p = 0.019). Coronavirus disease 2019 incidence was 16%, with 17% hospitalized and one death (8%). Despite low initial seroconversion rates post‐HSCT, antibody responses improved after the second dose. Early full re‐vaccination and boosters post‐HSCT are recommended to reduce mortality. Rituximab use and active GVHD were identified as risk factors, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCOVID-19SeroconversionSARS-CoV-2COVID-19 VaccinesHumansMiddle AgedFemaleMaleAdultAgedRetrospective StudiesAntibodies, ViralImmunization, SecondaryTransplantation, HomologousGraft vs Host DiseaseHematologic NeoplasmsVaccination

Stichwörter der Autor:innen

HSC transplantationSARS‐CoV‐2vaccines

Substanzen

COVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • The Royal Marsden NHS Hospital, Sutton, UK.
  • United Lincolnshire Hospitals NHS Trust, Lincoln, UK.

ORCID-Profile: Marios Tsoutsoukis, Emma Nicholson

Zitieren

APA

Tsoutsoukis, M., Anthias, C., Easdale, S., & Nicholson, E. (2024). Re‐vaccination against SARS ‐ CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates. British Journal of Haematology. https://doi.org/10.1111/bjh.19780

Vancouver

Tsoutsoukis M, Anthias C, Easdale S, Nicholson E. Re‐vaccination against SARS ‐ CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates. British Journal of Haematology. 2024. doi:10.1111/bjh.19780

BibTeX
@article{Tsoutsoukis2024,
  author = {Tsoutsoukis, Marios and Anthias, Chloe and Easdale, Sandra and Nicholson, Emma},
  title = {Re‐vaccination against SARS ‐ CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19780}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche